{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023274","form_type":"8-K","ticker":"STRO","cik":"0001382101","company_name":"SUTRO BIOPHARMA, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.383501+00:00","generated_at":"2026-06-22T03:12:46.877898+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sutro BioPharma Q3 revenue $25.1M, cash $287.3M; STRO-002 data at ASH, Phase 2 design by year end","bullets":["Revenue $25.1M (up from $8.5M YoY); total operating expenses $46.4M.","Cash, equivalents and marketable securities $287.3M as of Sep 30, 2022; projected runway into first half 2024.","STRO-002 oral presentation at ASH 2022 for pediatric AML; Phase 1 ovarian data and Phase 2 design expected by end 2022.","Vaxcyte positive Phase 1/2 data for VAX-24; Sutro to receive 4% royalties on worldwide net sales.","Astellas collaboration with $90M upfront received; Merck $10M milestone triggered."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023274","json":"https://secwatch.observer/filing/0000950170-22-023274.json","markdown":"https://secwatch.observer/filing/0000950170-22-023274.md","text":"https://secwatch.observer/filing/0000950170-22-023274.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/0000950170-22-023274-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/stro-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:12:46.877898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fdf764888d43e079041ed121ef4ac894b6c19e8","claim":"SUTRO BIOPHARMA, INC. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/0000950170-22-023274-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}